PPARG and diabetes mellitus: Peroxisome proliferator-activated receptor (PPARγ) agonists, such as thiazolidinediones (TZDs), used in the treatment of diabetes, have also been reported to show unwanted side effects, including weight gain, cardiovascular disease, fluid retention, bone fracture, and bladder cancer.